Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dendrobine** is a naturally occurring tetracyclic sesquiterpene alkaloid chiefly isolated from the medicinal orchid Dendrobium nobile Lindl. It displays a range of pharmacological activities including neuroprotective, antiviral (notably anti-influenza activity), anticancer (notably pro-apoptotic effects in cancer cell lines), anxiolytic, and anti-inflammatory effects. Mechanistically, dendrobine antagonizes β-alanine and taurine in the central nervous system and modulates presynaptic inhibition. It inhibits influenza A viral replication via binding the viral nucleoprotein (NP), restraining NP nuclear export, and impeding NP oligomerization. In oncology models, dendrobine promotes mitochondrial-dependent apoptosis through upregulating pro-apoptotic Bax and downregulating anti-apoptotic Bcl-2. Neuropharmacological studies indicate enhancement of neurotransmission, synaptic function, and serotonin levels, suggesting potential roles in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, and in mood regulation[1][2][4][6][7][13][15].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dendrobine.